Abstracts tagged "Anti-TNF therapy and rheumatoid arthritis (RA)"

Abstract Number: 1272 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 24-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve-Week Study Followed by a 12 -Week Open-Label Phase
M. Schiff¹, Ronald Goldblum² and John RP Tesser³, ¹University of Colorado, Denver, CO, ²CPC, Inc, Carlsbad, CA, ³AZ Arthritis Rheum Assoc, Paradise Valley, AZ
Background/Purpose: Certolizumab pegol (CZP), an inhibitor of TNF-alpha, has demonstrated rapid and sustained efficacy in RA patients. Switching from one anti-TNF therapy to another has…
Abstract Number: 483 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Literature On Discontinuation Rates of Biologics in Rheumatoid Arthritis
Setareh A. Williams¹, Victoria Porter², Victoria Zarotsky³, Sujatha Sundaram⁴, Elisabeth Nyman⁵, Cassie K. Gregson⁶ and Paul S. J. Miller⁶, ¹AstraZeneca LP, Wilmington, DE, ²OptumInsight, Mastic Beach, NY, ³OptumInsight, Calabasas, CA, ⁴OptumInsight, Hanover, NH, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Macclesfield, United Kingdom
Background/Purpose: To assess reasons for biologic discontinuation or switching in the treatment of rheumatoid arthritis (RA). Methods: A text mining strategy was developed to identify, from the biomedical…
Abstract Number: 374 • 2012 ACR/ARHP Annual Meeting
Prevalence of Biologic Utilization Over Calendar Time Among Medicare Beneficiaries with Rheumatoid Arthritis
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Lang Chen⁴, James Lewis⁵, Kevin Haynes⁶, Kenneth G. Saag⁷ and Jeffrey R. Curtis¹, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁷Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Prevalence of Biologic Utilization over Calendar Time among Medicare Beneficiaries with Rheumatoid ArthritisBackground/Purpose: The establishment of Medicare prescription drug coverage in 2006 and FDA…
Abstract Number: 379 • 2012 ACR/ARHP Annual Meeting
Persistency and Predictors of Persistency of Adalimumab Among Rheumatoid Arthritis (RA) Patients in a US Registry
Allan Gibofsky¹, Katherine C. Saunders², Arijit Ganguli³, Mary Cifaldi⁴, Shannon Grant⁵, Jerry Clewell⁴, Neelufar Mozaffarian⁴, James Shaw⁶, Reva McCaskill⁴, George W. Reed⁷ and Jeffrey D. Greenberg⁸, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²Corrona, LLC., Southborough, MA, ³AbbVie, North Chicago, IL, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Axio Research LLC, Seattle, WA, ⁶Global Health Economics and Outcomes Research, Abbott, Abbott Park, IL, ⁷University of Massachusetts Medical School, Worcester, MA, ⁸Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: There are limited observational data to guide physician decision-making when choosing to begin a patient on a new biologic treatment. Understanding real-world trends in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].